文献速递血栓与止血

艾美珠单抗与延长半衰期凝血因子Ⅷ替代药物相关的出血性和血栓性不良事件:2021年EudraVigilance数据

Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
PubMed 文献 · J Thromb Haemost · 2023-01-16

该研究基于EudraVigilance数据库2021年全年数据,比较艾美珠单抗与延长半衰期凝血因子Ⅷ产品报告的出血性和血栓性药物不良反应。艾美珠单抗出血性不良反应报告率较低(ROR 0.49),血栓性不良反应报告率较高(ROR 2.56)。约25%的血栓性不良反应与艾美珠单抗和艾帕克托α联合报告。

要点

  • 2021年EudraVigilance数据库中,艾美珠单抗报告406例不良反应,延长半衰期凝血因子Ⅷ产品报告376例。
  • 艾美珠单抗出血性不良反应ROR为0.49(95%CI 0.36-0.66),血栓性不良反应ROR为2.56(95%CI 1.18-5.59),对照为延长半衰期凝血因子Ⅷ产品。
  • 约25%的血栓性不良反应与艾帕克托α同时报告,提示与旁路制剂联用时的监测重要性。

核心结论

  • 2021年EudraVigilance报告分析显示,与延长半衰期凝血因子Ⅷ产品相比,艾美珠单抗的出血性不良反应报告率较低而血栓性不良反应报告率较高。
  • 这些信号强调了对血友病新药进行监测的重要性,尤其是与旁路制剂联合使用时。

研究设计与样本

  • 研究收集了2021年1月1日至2021年12月31日期间EudraVigilance数据库中艾美珠单抗或延长半衰期凝血因子Ⅷ产品治疗期间报告的全部药物不良反应。
  • 计算比例报告比和报告比值比(ROR)及其95%CI,以表达艾美珠单抗与延长半衰期凝血因子Ⅷ产品之间出血性和血栓性不良反应的报告频率比。

主要发现

  • 艾美珠单抗报告406例不良反应,延长半衰期凝血因子Ⅷ产品报告376例不良反应。
  • 艾美珠单抗的出血性和血栓性不良反应分别为232例和24例,延长半衰期凝血因子Ⅷ产品的出血性和血栓性不良反应分别为275例和9例。
  • 约25%的血栓性不良反应与艾帕克托α同时报告。
  • 与延长半衰期凝血因子Ⅷ产品相比,艾美珠单抗出血性不良反应的ROR为0.49(95%CI 0.36-0.66),血栓性不良反应的ROR为2.56(95%CI 1.18-5.59)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety concerns for an increased risk of thrombotic complications in patients with hemophilia A have been pointed out, particularly during nonreplacement treatment with emicizumab and concomitant bypassing agents. Surveillance with the Roche Global Database reporting adverse events for emicizumab has been discontinued on May 2021. OBJECTIVES: The objective of this study was to evaluate the reporting rate of hemorrhagic and thrombotic adverse drug reactions (ADRs) associated with nonreplacement (emicizumab) and replacement extended half-life (EHL) factor VIII (FVIII) products as retrieved from the EudraVigilance database. METHODS: Total ADR reported during treatment with emicizumab or EHL FVIII products from January 1 to December 31, 2021, were collected. The proportional reporting ratio and the reporting odds ratio (ROR) with their 95% CIs were calculated to express the hemorrhagic and thrombotic ADR reporting frequency ratio between emicizumab and EHL FVIII products. RESULTS: Overall, 406 and 376 ADRs were reported for emicizumab and for EHL FVIII products, respectively. Hemorrhagic and thrombotic ADRs were 232 and 24 for emicizumab and 275 and 9 for the EHL FVIII products. Approximately 25% of thrombotic ADRs were reported concomitantly with eptacog alfa. ROR of 0.49 (95% CI, 0.36-0.66) for hemorrhagic and of 2.56 (95% CI, 1.18-5.59) for thrombotic ADRs were obtained for emicizumab compared with EHL FVIII products. CONCLUSION: The analysis of 2021 EudraVigilance reports shows a lower reporting rate of hemorrhagic ADR vs a higher reporting rate of thrombotic ADR for emicizumab than for EHL FVIII products. These signals stress the importance of monitoring novel drugs in hemophilia, particularly when administered in association with bypassing agents.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Abbattista M, Ciavarella A, Noone D, et al. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. J Thromb Haemost. 2023. PMID: 36710195. doi:10.1016/j.jtha.2023.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。